Tag: Bayer

Bayer initiates Phase II study with first-in-class anti-alpha2 antiplasmin antibody in patients with deep vein thrombosis

BERLIN–(BUSINESS WIRE)–Bayer announced today the start of a Phase II clinical trial (SIRIUS study) with BAY3018250, an investigational first-in-class anti-alpha2 antiplasmin (anti-α2ap) antibody in patients with deep vein thrombosis (DVT). The results of this study might provide evidence of anti-α2ap […]

Bayer Expands Clinical Development Program Investigating Finerenone for Potential Treatment of Heart Failure

WHIPPANY, N.J.–(BUSINESS WIRE)– Bayer announced it is further investing in MOONRAKER— its clinical development program to investigate Kerendia® (finerenone) as a potential treatment for heart failure (HF) — with the initiation of three additional investigator-sponsored collaborative studies.1,2,3,4 Recruiting approximately 15,000 patients, MOONRAKER is […]

Bayer Partners with Huma on Bayer® Aspirin Heart Risk Assessment Online Educational Tool to Raise Awareness of Heart Health and its Risk Factors

Huma’s predictive algorithm will power a new global online patient engagement tool* that provides an accessible solution for heart health education NEW YORK, Feb. 1, 2023 /PRNewswire/ — Huma Therapeutics Limited (“Huma”), a leading global digital health company, and Bayer, a leading […]

Bayer Acquires Blackford Analysis Ltd. Bolstering the Company’s Position in Digital Medical Imaging

Acquisition is part of Bayer’s innovation strategy in radiology Blackford Analysis provides cutting-edge radiology AI platform technology Following closing of the acquisition, Blackford Analysis to become part of Bayer’s well established “arm’s length” operating model to preserve the company’s entrepreneurial […]

Bayer to Highlight New Cardiovascular and Renal Data at ACC.22, Including Late-Breaking Presentations for KERENDIA® (finerenone) as Well as Oral Factor XIa Inhibitor (asundexian) Program

Further analysis from FIDELITY, a prespecified pooled analysis of FIDELIO-DKD and FIGARO-DKD, explores the effect of KERENDIA® (finerenone) on cardiovascular (CV) and kidney outcomes in patients with chronic kidney disease associated with type 2 diabetes, with and without history of CV […]